# A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

> **NCT00042302** · PHASE3 · TERMINATED · sponsor: **QLT Inc.** · enrollment: 540 (—)

## Conditions studied

- Stage IIIb Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **PROCEDURE:** Chemotherapy
- **DRUG:** tariquidar + paclitaxel/carboplatin
- **DRUG:** placebo + paclitaxel/carboplatin

## Key facts

- **NCT ID:** NCT00042302
- **Lead sponsor:** QLT Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-06
- **Primary completion:** 2003-07
- **Final completion:** 2003-07
- **Target enrollment:** 540 (—)
- **Last updated:** 2012-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00042302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00042302, "A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00042302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*